Aptevo Therapeutics - APVO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.74
▲ +0.03 (4.25%)

This chart shows the closing price for APVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aptevo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APVO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Aptevo Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.74.

This chart shows the closing price for APVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Aptevo Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2023Alliance Global PartnersInitiated CoverageBuyLow
8/12/2022Piper SandlerLower Target$880.00 ➝ $572.00Low
5/13/2022Piper SandlerLower Target$3,036.00 ➝ $880.00High
12/22/2021UBS GroupDowngradeBuy ➝ NeutralMedium
11/15/2021Roth CapitalLower TargetBuy$2,200.00 ➝ $1,584.00High
5/28/2021Roth CapitalLower TargetBuy$2,816.00 ➝ $2,200.00Low
11/11/2020Piper SandlerReiterated RatingOverweightLow
8/14/2020Piper SandlerBoost Target$1,056.00 ➝ $1,408.00High
5/15/2020Piper SandlerLower Target$1,056.00 ➝ $814.00Medium
3/4/2020Roth CapitalReiterated RatingBuyMedium
3/2/2020Piper SandlerLower Target$132.00 ➝ $74.80High
10/4/2019Piper Sandler CompaniesLower Target$198.00 ➝ $132.00Low
5/23/2019Roth CapitalReiterated RatingBuyLow
(Data available from 4/24/2019 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aptevo Therapeutics logo
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $0.74
Low: $0.70
High: $0.76

50 Day Range

MA: $4.43
Low: $0.71
High: $7.48

52 Week Range

Now: $0.74
Low: $0.67
High: $91.96

Volume

358,578 shs

Average Volume

214,030 shs

Market Capitalization

$316.57 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptevo Therapeutics?

The following Wall Street research analysts have issued research reports on Aptevo Therapeutics in the last twelve months: Alliance Global Partners, and StockNews.com.
View the latest analyst ratings for APVO.

What is the current price target for Aptevo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aptevo Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aptevo Therapeutics in the next year.
View the latest price targets for APVO.

What is the current consensus analyst rating for Aptevo Therapeutics?

Aptevo Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APVO will outperform the market and that investors should add to their positions of Aptevo Therapeutics.
View the latest ratings for APVO.

What other companies compete with Aptevo Therapeutics?

How do I contact Aptevo Therapeutics' investor relations team?

Aptevo Therapeutics' physical mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company's listed phone number is (206) 838-0500 and its investor relations email address is [email protected]. The official website for Aptevo Therapeutics is www.aptevotherapeutics.com. Learn More about contacing Aptevo Therapeutics investor relations.